Asset Details
Do you wish to reserve the book?
Biologics for the Treatment of Pyoderma Gangrenosum: A Narrative Review
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Biologics for the Treatment of Pyoderma Gangrenosum: A Narrative Review
Do you wish to request the book?
Biologics for the Treatment of Pyoderma Gangrenosum: A Narrative Review
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Biologics for the Treatment of Pyoderma Gangrenosum: A Narrative Review
2025
Overview
Pyoderma gangrenosum (PG) is a rare and complex neutrophilic dermatosis characterized by the rapid onset of painful ulcers with undermined margins and peripheral erythema. This review focuses on the emerging role of biologic therapies in the management of PG. We systematically analyzed studies, highlighting the efficacy, safety, and clinical applications of biologic agents. Despite limited randomized controlled trials, biologics like infliximab and adalimumab show promising results, particularly in refractory cases. In addition, emerging evidence supports the role of non‐TNF agents such as IL‐1, IL‐17, IL‐23, and IL‐36 inhibitors, as well as JAK inhibitors, expanding the therapeutic armamentarium for refractory PG. Further research is essential to establish standardized guidelines for their use.
Publisher
John Wiley & Sons, Inc
Subject
